Stock Track | Adaptive Biotechnologies Soars 5% in Pre-Market as Full Year Earnings Beat Expectations

Stock Track

Feb 13

Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.

ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.

Looking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1160569989"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1160569989\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1160569989?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-13 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160569989","market":"hk","top_or_hot":-1,"title":"Stock Track | Adaptive Biotechnologies Soars 5% in Pre-Market as Full Year Earnings Beat Expectations","media":"Stock Track","content":"<p>Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.</p>\n\n<p>ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.</p>\n\n<p>Looking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Adaptive Biotechnologies Soars 5% in Pre-Market as Full Year Earnings Beat Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Adaptive Biotechnologies Soars 5% in Pre-Market as Full Year Earnings Beat Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-13 23:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.</p>\n\n<p>ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.</p>\n\n<p>Looking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADPT","symbol_name":"Adaptive Biotechnologies Corp","start_time":0,"source_url":"","article_id":"1160569989","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160569989","pubTimestamp":1739461485,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Adaptive Biotechnologies Corp  jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADPT":"Adaptive Biotechnologies Corp"},"translate_title":"股票赛道Adaptive Biotechnologies盘前飙升5%，全年盈利超出预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADPT":1},"content_text":"Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.\nADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.\nLooking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}